Journal
CELL METABOLISM
Volume 23, Issue 4, Pages 712-724Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2016.03.004
Keywords
-
Categories
Funding
- Wihuri Foundation
- Academy of Finland [271845]
- Cancer Society of Finland
- Sigrid Juselius Foundation
- European Research Council [ERC-2010-AdG-268804]
- Leducq Foundation [11CVD03]
- European Union [305707]
- NIH [U24 DK059637, RO1 DK054902]
- Academy of Finland (AKA) [271845, 271845] Funding Source: Academy of Finland (AKA)
Ask authors/readers for more resources
Impaired angiogenesis has been implicated in adipose tissue dysfunction and the development of obesity and associated metabolic disorders. Here, we report the unexpected finding that vascular endothelial growth factor B (VEGFB) gene transduction into mice inhibits obesity-associated inflammation and improves metabolic health without changes in body weight or ectopic lipid deposition. Mechanistically, the binding of VEGFB to VEGF receptor 1 (VEGFR1, also known as Flt1) activated the VEGF/VEGFR2 pathway and increased capillary density, tissue perfusion, and insulin supply, signaling, and function in adipose tissue. Furthermore, endothelial Flt1 gene deletion enhanced the effect of VEGFB, activating the thermogenic program in subcutaneous adipose tissue, which increased the basal metabolic rate, thus preventing diet-induced obesity and related metabolic complications. In obese and insulin-resistant mice, Vegfb gene transfer, together with endothelial Flt1 gene deletion, induced weight loss and mitigated the metabolic complications, demonstrating the therapeutic potential of the VEGFB/VEGFR1 pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available